Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target

MT Newswires Live09-13

Neurocrine Biosciences (NBIX) said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.

"It failed to replicate the cognitive endpoints data seen in the earlier Interact study, due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms," the company said.

Neurocrine plans to halt further development of luvadaxistat and focus on the advancement into phase 3 clinical development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder, Chief Medical Officer Eiry Roberts said.

The company's shares were down about 1% in after-hours activity.

Price: 120.00, Change: -1.28, Percent Change: -1.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467973496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467973496","market":"sg","top_or_hot":-1,"title":"Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences (NBIX) said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.</p><p>\"It failed to replicate the cognitive endpoints data seen in the earlier Interact study, due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms,\" the company said.</p><p>Neurocrine plans to halt further development of luvadaxistat and focus on the advancement into phase 3 clinical development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder, Chief Medical Officer Eiry Roberts said.</p><p>The company's shares were down about 1% in after-hours activity.</p><p>Price: 120.00, Change: -1.28, Percent Change: -1.06</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 05:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurocrine Biosciences (NBIX) said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171311.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467973496","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467973496","pubTimestamp":1726175436,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences  said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.\"It failed to replicate the cognitive endpoints data seen in the earlier Interact study, due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms,\" the company said.Neurocrine plans to halt further development of luvadaxistat and focus on the advancement into phase 3 clinical development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder, Chief Medical Officer Eiry Roberts said.The company's shares were down about 1% in after-hours activity.Price: 120.00, Change: -1.28, Percent Change: -1.06","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","NBIX":"神经分泌生物科学"},"translate_title":"Neurocrine计划在研究未能达到目标后停止Luvadaxistat的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":0.9},"content_text":"Neurocrine Biosciences (NBIX) said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.\"It failed to replicate the cognitive endpoints data seen in the earlier Interact study, due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms,\" the company said.Neurocrine plans to halt further development of luvadaxistat and focus on the advancement into phase 3 clinical development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder, Chief Medical Officer Eiry Roberts said.The company's shares were down about 1% in after-hours activity.Price: 120.00, Change: -1.28, Percent Change: -1.06","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467973496"}